## Efficacy Of Low Dose Doxycycline In The Treatment Of Periodontal Disease - A Systematic Review

## Dr. Lukram Slim\*, Dr. Sachit Anand Arora\*\*, Dr. Fatima Gilani\*

\*3<sup>rd</sup>Year PG Student, Department Of Periodontics, \*\*Principal &Professor Department Of Periodontics, Department Of Periodontics, I.T.S. Dental College And Research Centre, Greater Noida Knowledge Park III, 201308, India

Abstract:Background:Periodontal instrumentation is accessible to a certain limit, as subgingival calculus is difficult to remove completely in cases of deep pockets and furcation defects. Host modulating agents aim to inhibit arachidonic acid pathways, modulate MMPs, bone remodeling, and regulate immune and inflammatory responses. This systematic review aimsto find the effects of Low Dose Doxycycline (LDD) as local drug delivery systems and sub-antimicrobial dose doxycycline for the treatment of periodontal disease. Material And Methods: Electronic database searched were: Pubmed, Medline, Scopous and Ebsco was performed using MeSH terms: low dose doxycycline, subantimicrobial dose doxycycline, chemically modified doxycycline, doxycycline, doxycycline hyclate, atridox and periostat. Articles published between years 2008-2019 were reviewed. Result: A Systematic review methodology was followed and database searching was done which yields 422 records. Records from year 2008 - 2019 were taken into consideration. After inclusion and exclusion accordingly, A total of 10 studies were systematically reviewed. Non surgical or surgical periodontal therapy is more effective in reducing periodontal disease when low dose doxycycline is used as an adjunct either locally or systematically delivered. Conclusion: Subantimicrobial Dose Doxycycline (SDD) is commonly accepted as a host response modifier and it Subantimicrobial Dose Doxycycline (SDD) which down regulates the activity of MMPs. Also, doxycycline provides long-term post-treatment effects. Based in the inference drawn from this systematic review, non surgical or surgical periodontal therapy is more effective in reducing periodontal disease when low dose doxycycline is used as an adjunct, delivered either locally or systematically. [Slim L Natl J Integr Res Med, 2021; 12(4):66-72]

**Key Words:**Low Dose Doxycycline, Subantimicrobial Dose Doxycycline, Doxycycline, Doxycycline Hyclate, Atridox And Periostat

**Author for correspondence:** Dr. Lukram Slim, 3rd Year PG Student, Department Of Periodontics, I.T.S. Dental College And Research Centre, Knowledge Park III, Greater Noida. E-Mail: lukramslim@gmail.com

Introduction: The tooth and its supporting structures are coated with plaque which acts as a host to a plethora of microorganisms<sup>1</sup>. Periodontal disease is of two types, namely acute periodontitis. periodontitis and chronic Interaction between symbiotic microbes and pathogenic microbes and the host they colonize are the main reason for periodontal tissue breakdown. The primary clinical feature includes gingival enlargement, pocket formation, loss of attachment and alveolar bone loss. The goal of periodontal therapy is to preserve, maintain and improve the health of tooth and implant supporting structures, and to reduce any future risk for the disease.

Scaling and root planning is considered the basis of periodontal therapy as it includes removal of supragingival and subgingival plaque and calculus, but to an extent<sup>2</sup>. Periodontal instrumentation is accessible to a certain limit, as subgingival calculus is difficult to remove completely in cases of deep pockets and furcation defects. Considering these drawbacks, host modulation therapy comes into the picture. Host modulating agents aim to inhibit arachidonic acid pathways, modulate MMPs, bone remodeling, and regulate immune and inflammatory responses<sup>3</sup>.

Tetracycline is seen to be used widely in periodontal therapy which modulates host response to periopathogenic bacteria. It has been suggested to be used as an adjunctive therapy to scaling and root planning. Low dose doxycycline (LDD) as local drug delivery systems and subantimicrobial dose doxycycline administered systematically are two widely used of doxycycline for the treatment of periodontal disease, without additional systemic side-effects<sup>4</sup>.

**Material & Methods:** <u>Literature Search:</u> This systematic review is based on PRISMA (preferred reporting items for systematic review and meta-

This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creative commons.org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for any purpose, even commercially, provided the original work is properly cited and states its license.

NJIRM 2021; Vol.12(4) July – August

analysis). Literature was searched systematically and studies were identified based on the PICO (Glossary of Evidence Terms 2007): Electronic database searched were: Pubmed, Medline, Scopous and Ebsco was performed using MeSH terms: low dose doxycycline, subantimicrobial dose doxycycline, chemically modified doxycycline, doxycycline, hyclate, atridox and periostat.

Articles published between years 2008-2019 were reviewed. The selected titles were reviewed by two authors- Lukram Slim and Sachit Anand Arora and were included based on following inclusion and exclusion criteria.

<u>Study Selection:Focused Questions:</u> Effects of sub antimicrobial dose doxycycline on periodontal disease pathogens. Effect of local drug delivery of doxycycline in treatment of chronic and aggressive periodontal patients.

Efficacy of low dose doxycycline in periodontal treatment. Effect of long germ use of doxycycline.

<u>Inclusion Criteria:</u> Systematic Review. Meta-Analysis. Cohort Study. Randomized Control Study. Human studies. Longitudinal studies. Case series.

Exclusion Criteria: Publications in any language. other than English. Animal Studies. In Vitro studies. Patients with known systemic disease. Patient on medication from last 6 months.

## **Results:**

<u>Study Identification:</u> A Systematic review methodology was followed and database searching was done which yields 446 records. Additional sources yielded 24 more records. 48 duplicate records were removed, leaving 422 records to be screened further. Records from year 2008 -19 were taken into consideration<sup>3-23</sup>.

209 records were found. 213 records were further reviewed and 88 records were excluded on the basis of availability of full texts. 125 articles were reviewed, 28 articles were excluded on the basis of language other than English.

From total of 97 records, 14 animal studies, 20 in vitro studies and 30 studies which used methodology not appropriate for this review and 23 case reports were excluded. A total of 10 studies are systematically reviewed.

Figure 1: A Prisma Chart Showing The Inclusion Of Studies In The Review Process Outline Of Systematic Methodology




 Table 1: Overview Of The Details, Study Designs, Sample Size, Age, Interventions, Parameters Significance

 Intervals (P Value) And Inferences

			interv	ais (P value) An	u meren		
Researchers	Study	Sample	Age	Test Groups/	Para	Р	Inference
& Year	Design	size	(year)	Intervention	meter	value	
Emingil et.al	randomized	Sample	31-61	Group A-	PPD	p<	SSD+SRP showed a statistically
2019 <sup>24</sup>	,double-	Size = 30		SDD(20mg	CAL	0.025	significant improvement for all
	blind,			b.i.d for 3	GCF		clinical parameters in the first 3
	placebo-			months)+SRP			months which was maintained
	controlled,			Group B-			throughout the 12 month i.e, no
	parallel-			PLACEBO			statistically significant changes in
	arm study			(b.i.d. for 3			clinical parameters were seen from
				months)+SRP			3-12 months
Ahamed	Parallel	Subject	25-55	Control	PPD	р <	SRP+ 10% Doxycycline hyclate shows
et.al 2016 <sup>25</sup>	design,	14		group=SRP	GAL	0.05	significant improvement in PPD and
	Aclinical	Sample=		Test group=			GAL
	and	30		SRP+			
	microbiolog			ATRIDOX			
	ical study						
Pârvu AE et	double-	Sample=	30-60	Group A=	PPD	p<	At the end of the 3 month trial, they
al 2012 <sup>27</sup>	blind,	174		SRP+ Placebo	CAL	0.01	were able to achieve a statistically
	placebo-			Group B			significant result in all the clinical
	controlled,			SRP+SDD			parameters checked.
	randomize,						
	3-month						
	clinical						
	study with						
	2 treatment						
	arms: SRP +						
	SDD or SRP						

NJIRM 2021; Vol.12(4) July - August

eISSN: 0975-9840

	+placebo						
Mukhatar Ahmed Javali, K. L. Vandana 2012 <sup>26</sup> Emingil,	A randomized cross-over split mouth design,clini cal study randomize,	Subject 4(2AP,2 CP)130 sites Subject	As per AAP 1999 34-61	Control groupA= SRP ,GroupB=SRP +Doxycycline GroupC= doxycycline Group A	CAL DT PPD	p< 0.001 p<	doxycycline hyclate 10% gel (Atridox) is as effective as SRP in reducing the CAL and Delta Temperature
Gu <sup>°°</sup> rkan, Atilla, Kantarci 2011 <sup>30</sup>	doublemas ked, placebo- controlled experiment	= 46	57 01	SRP+ SDD Group B SRP + Placebo	CAL GCF	0.05	significant difference was seen in PPD of the SDD group throughout the study, whereas, no improvement was seen in CAL and GCF as compared to the placebo group and from the baseline. CAL was seen to improve in both the groups in the first 3 months and was maintained throughout.
Rao et.at 2011 <sup>29</sup>	Parallel design, single- blinded, Randomize d control trial	Subject 14 (4F 10M) 20 sites	20-50	Control Group SRP+DOXYCY CLINE at baseline only Test group SRP+DOXYCY CLINE At baseline, 1 month and 3 months	PPD, RAL	p < 0.05	SRP+DOXYCYCLINE shows significant improvement in PPD and RAL
Tu¨ter, Serdar, Kurtisx, et al. 2010 <sup>28</sup>	Randomize d placebo controlled clinical trial	Sample = 58 CP=47 Healthy =17	36-51	Group A= control (healthy group)Group B=SRP+ place bo, Group C= SRP+SDD	PPD CAL GCF MMP- 8 MMP- 13	p < 0.001	Adjunctive SDD therapy can improve the clinical parameters, such as PPD and CAL and these clinical improvements are reflected by the controlled level of MMPs in CP patients after the therapy.
Emingil, Atilla, Sorsa, Tervahartial a 2008 <sup>32</sup>	Randomize d, double- masked, placebo- controlled, parallel- arm study	Subject= 30	37-61	Group A (SRP+ SDD) Group B (SRP+Placeb O	PPD CAL GCF EMMP RIN	p< 0.025	A statistically significant result was obtained in the SRP+SDD group compared to the placebo group at 3 months and it was maintained in the later months
Bogren et. At 200 <sup>31</sup>	Randomise d Controlled Clinical Trial	Subject = 128 Sample= 30	≥20 years	Test group= 60(SPT+Local Ab)Control group = 64 (SPT)	PPD RAL	p< 0.001	Statistically significant beneficial effects on PPD and RAL were observed with the adjunctive use of locally delivered controlled- release doxycycline in periodontitis patients.
Ranjan Gupta, Nymphean Pandit, Shweta	single center, randomized , controlled trial, split	Subject= 30 90 sites	25-75 years	Control groupA-(SRP) GroupB- (SRP+ DH) GroupC-(SRP	PPD CAL	p< 0.001	Either DT or CHX, used as an adjunct have shown marked improvement than SRP alone

NJIRM 2021; Vol.12(4) July – August

	-			i.	
Aggarwal,As	mouth		+CHX)		
			,		
hish Verma	study.				
2008 <sup>33</sup>					
2000					

**Discussion:** Scaling and root planing has been considered as the gold standard for the treatment periodontal diseases but, it does not lead to major clinical improvements in cases of advanced disease and deep periodontal pockets<sup>5</sup>.

This is probably because scaling and root planing alone does not cause a sufficiently deep change in the subgingival microbial composition to achieve and maintain a profile compatible with periodontal health longitudinally. Mechanical removal of bacterial plaque and calculus, combined with proper oral hygiene measures are prevent further periodontal known to attachment loss in most individuals by reducing total sub gingival bacteria. But, some individuals continue to experience attachment loss due to the presence of periodontal pathogens like Porphyromonas qinqivalis, Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum, Treponema denticola, etc. which invades the periodontal tissues and resides in the depth of the sulcus also in the area of furcation, where the periodontal instruments are hard to reach, or due to poor host defense mechanisms<sup>4</sup>. The use of SDD as an adjunctive therapy to SRP additional benefits in the provides an management of chronic periodontitis compared to periodontal non-surgical treatment alone. Also, it provided long-term post-treatment effects.

However, long-term administration of doxycycline might develop antibiotic resistance.

But, in contrary to this, studies have proven that SDD (20 mg twice daily) administered for just 2 weeks inhibited collagenase activity by 60–80% in the gingival tissues of patients with chronic periodontitis (Golub *et al.* 1990)<sup>6</sup>. Collagenase activity was also significantly reduced in GCF collected from these patients. This dosing regimen could prevent periodontitis progression without the emergence of doxycycline-resistant microorganisms or other typical antibiotic side-effects (Golub *et al.* 1994)<sup>7</sup>.

Pharmacokinetic studies in human volunteers have demonstrated that 20 mg doxycycline twice daily resulted in peak serum concentrations of 0.7–0.8 mg/ml and steady-state concentrations of approximately 0.4 mg/ml (Caton 1999)<sup>8</sup>. This is below the minimum inhibitory level concentration (MIC) determined for doxycycline in vitro for the great majority of the bacteria isolated from subgingival plaque (Walker et al. 1985, Walker 1996)<sup>9,10</sup>, and is well below the blood levels of 3–4 mg/ml produced by antibiotic doses of 100-200 mg (Walker et al. 2000). From perspective, therefore, at this а (sub antimicrobial) dose of 20 mg twice daily, doxycycline does not appear likely to exert any significant selection pressure resulting in the development of resistant strains, or have any influence on periodontal bacteria.

Doxycycline related suppression and inhibition of MMPs mainly target on three types of tissues: Epithelieum- Inhibition of production of epithelial derived MMPs by inhibiting cellular expression and synthesis.<sup>9</sup>, Connective tissue: Directly inhibit the MMPs by cationic chelation. Inhibits the oxidative action of latent MMPs. Down regulates the expression of key inflammatory cytokines such as IL-1, IL-6, TNF- $\alpha$  and PGE2.

Scavenges and inhibits the production of reactive oxygen species produced by PMNs Stimulates fibroblasts and collagen production. And Alveolar bone: - Reduces the osteoclastic activity and bone resorption, Blocks osteoclast MMPs, Stimulates osteoblast activity and bone formation.

The aim of the present systematic review is to check the efficacy of low dose doxycycline in treatment of periodontal diseases. By the term low dose doxycycline, we understand that low dose of doxycycline could be in the form of subantimicrobial oral dose or what is known as local drug delivery.

Clinical parameters such as PPD, CAL, DT, RAL, GCF (MMP-8,-13, EMMPRIN) can be used to check the effectiveness of the drug during a certain period of the time of the study. This systematic review evaluated published studies showing the efficacy of low dose doxycycline, delivered systematically or locally, for the treatment of periodontal diseases.

In a series of studies conducted by Emingil et al.

(2019,2011,2008)<sup>24,30,32,</sup> comparing the subantimicrobial dose doxycycline with placebo drugs, a statistically significant result was achieved in the SDD group, with marked improvement in PPD, CAL and RAL. The results were consistent throughout the course of the studies. Tuter *et. al.* in their randomised placebo controlled clinical trial showed statistically significant decrease in PPD in the group which received SDD as an adjunct to SRP.

Paruv *et al.* concluded in their study that SRP with SDD as an adjunctive gives a statistically significant result in the first three months.

Ahamed S. *et al.* concluded that that 10% doxycycline gel used as an adjunct therapy to scaling and root planning shows significant improvement in the parameters along the study period of 180 days. Microbial analysis has also shown significant improvement at 90 days.

K.L.Vandana *et al.* in their study 10% doxycycline alone nor SRP alone didn't provide any statistically significant result whereas, doxycycline when used as an adjunct provided a statistically significant result. for the same.

Rao *et al*<sup>29</sup>. in 2011 conducted a parallel designed, randomized control trial showed that there were no statistically significant results between PPD and RAL as, doxycycline is effective for treatment of periodontal diseases whether given at baseline only or at baseline and 3 months both. In another study by Bogren et al. comparing surgical periodontal therapy with and without local drug delivery of doxycycline. Results stated that patients who received doxycycline with SPT showed statistically significant PPD and RAL compared to SPT alone. Gupta R. et al. showed a statistically significant improvement in the PPD and CAL of the two groups where an adjunct were used, compared to the group where only SRP was given along the time period of the study.

Based in the inference drawn from this systematic review, non surgical or surgical periodontal therapy is more effective in reducing periodontal disease when low dose doxycycline is used as an adjunct either locally or systematically delivered.

**Conclusion:** Periodontitis is a group of diseases characterized by destruction of the periodontal attachment apparatus supporting the teeth. It

has been well established that periodontal disease is the result of bacterial infection. The elimination of these microbial pathogens in the subgingival space is the primary objective of The treatment periodontal therapy. of periodontal diseases consists mainly of mechanical debridement of the affected root surface (which is considered a gold standard) along with reducing the total bacterial load and changing the environmental conditions of these microbial niches, and here comes the role of antibiotics.

Various antibiotics such as minocycline, tetracycline, metronidazole, and hexidine and anti- inflammatory agents, such as flurbiprofen and triclosan, have been used for the treatment of periodontitis in the past years.

Tetracycline family (tetracycline, minocycline and doxycycline) and an antiseptic consisting of chlorhexidine are more commonly used. Of these, subantimicrobial dose doxycycline (SDD) is commonly accepted as a host response modifier and it subantimicrobial dose doxycycline (SDD) which down regulates the activity of MMPs. Also, doxycycline provides long-term post-treatment effects.

Subantimicrobial doses, doxycycline is an inhibitor of matrix metalloproteases, and has been used in various experimental systems. With the understanding of periodontal disease and the treatment methods, various local delivery systems have been designed without the systemic side effects of antibiotics.

## **References:**

 Loesche WJ, Grossman NS. Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment. Clin Microbiol Rev. 2001;14(4):727-752.

doi:10.1128/CMR.14.4.727-752.2001

- Kamath DG, Umesh Nayak S. Detection, removal and prevention of calculus: Literature Review. Saudi Dent J. 2014;26(1):7-13. doi:10.1016/j.sdentj.2013.12.003
- 3. Elavarasu S, Sekar S, Murugan T. Host modulation by therapeutic agents. J Pharm Bioallied Sci. 2012;4(Suppl 2):S256-S259.
- Kalsi R, Vandana KL, Prakash S. Effect of local drug delivery in chronic periodontitis patients: A meta-analysis. J Indian Soc Periodontol. 2011;15(4):304-309.

- 5. Tariq M, Iqbal Z, Ali J, et al. Treatment modalities and evaluation models for periodontitis. Int J Pharm Investig. 2012;2(3):106-122.
- Kapoor A, Malhotra R, Grover V, Grover D. Systemic antibiotic therapy in periodontics. Dent Res J (Isfahan). 2012;9(5):505-515.
- Golub LM, Ciancio S, Ramamamurthy NS, Leung M, McNamara TF. Low-dose doxycycline therapy: effect on gingival and crevicular fluid collagenase activity in humans. J Periodontal Res. 1990 Nov;25(6):321-30.
- Caton, J.G., Jr., Greenwell, H., Mahanonda, R., Williams, R., Zappa, U., Claffey, N., Mariotti, A. and Zackin, J. (1999), Consensus Report: Dental Plaque-Induced Gingival Diseases. Annals of Periodontology, 4: 18-19.
- Liu, Jie, and Raouf A Khalil. "Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders." Progress in molecular biology and translational science vol. 148 (2017): 355-420.
- 10.Kapoor A, Malhotra R, Grover V, Grover D. Systemic antibiotic therapy in periodontics. Dent Res J (Isfahan). 2012;9(5):505–515.
- 11.Rafiei M, Kiani F, Sayehmiri F, Sayehmiri K, Sheikhi A, Zamanian Azodi M. Study of Porphyromonas gingivalis in periodontal diseases: A systematic review and metaanalysis. Med J Islam Repub Iran. 2017;31:62.
- 12.Tiwari G, Tiwari R, Sriwastawa B, et al. Drug delivery systems: An updated review. Int J Pharm Investig. 2012;2(1):2–11.
- 13.Nair SC, Anoop KR. Intraperiodontal pocket: An ideal route for local antimicrobial drug delivery. J Adv Pharm Technol Res. 2012;3(1):9–15.
- 14.Silva N, Abusleme L, Bravo D, et al. Host response mechanisms in periodontal diseases. J Appl Oral Sci. 2015;23(3):329–355.
- 15.Franco C, Patricia HR, Timo S, Claudia B, Marcela H. Matrix Metalloproteinases as Regulators of Periodontal Inflammation. Int J Mol Sci. 2017;18(2):440.
- 16.Kaur CP, Jindal V, Malhotra R, Jaggi D, Goel A, Kaur R. Perioceutics-A review. Indian J Dent Sci 2017;9, Suppl S1:44-8
- 17.Leeyaphan C, Ong JJ, Chow E, Kong F, Hocking JS, Bissessor M, et al. Systematic Review and Meta-Analysis of Doxycycline Efficacy for Rectal Lymphogranuloma Venereum in Men

Who Have Sex with Men. Emerg Infect Dis. 2016;22(10):1778-1784.

- 18.Hsi-Ming Lee, Sebastian G. Ciancio, Gülay Tüter, Maria E. Ryan, Eugene Komaroff, Lorne M. Golub. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a nonsteroidal anti-inflammatory drug. J Periodontol. 2004 Mar; 75(3): 453–463.
- 19.Kapoor A, Malhotra R, Grover V, Grover D. Systemic antibiotic therapy in periodontics. Dent Res J (Isfahan). 2012;9(5):505–515.
- 20.Golub LM, Lee HM, Stoner JA, et al. Subantimicrobial-dose doxycycline modulates gingival crevicular fluid biomarkers of periodontitis in postmenopausal osteopenic women. J Periodontol. 2008;79(8):1409–1418.
- 21.Valentín S, Morales A, Sánchez JL, Rivera A. Safety and efficacy of doxycycline in the treatment of rosacea. Clin Cosmet Investig Dermatol. 2009;2:129–140.
- 22.American Academy of Periodontology. The pathogenesis of periodontal diseases (position paper). J Periodontol 1999;70:457-70.
- 23.Pietri JE, Tiffany C, Liang D. Disruption of the microbiota affects physiological and evolutionary aspects of insecticide resistance in the German cockroach, an important urban pest. PLoS One. 2018;13(12):207-85.
- 24. Gülnur Emingil, Ali Gürkan , Taina Tervahartiala , Marcela Hernandez, Semiha Özgül , Timo Sorsa, and Saeed Alassiri Adjunctive Effects of a Sub-Antimicrobial Dose of Doxycycline on Clinical Parameters and Potential Biomarkers of Periodontal Tissue Catabolism in Dent. J. 2019:7(9):01-15
- 25.Alina Elena Pârvu, Sandu Florin Alb, Alexandra Crăciun, Marian Aurel Taulescu Efficacy of subantimicrobial-dose doxycycline against nitrosative stress in chronic periodontitis in Acta Pharmacologica Sinica (2013) 34: 247– 254
- 26.Mukhatar Ahmed Javali, K. L. Vandana A comparative evaluation of atrigel delivery system (10% doxycycline hyclate) Atridox with scaling and root planing and combination therapy in treatment of periodontitis: A clinical study in journal of clinical periodontology. 2012:16(1):43-48
- 27.Alina Elena Pârvu, Sandu Florin Alb, Alexandra Crăciun, Marian Aurel Taulescu. Efficacy of subantimicrobial-dose doxycycline against nitrosative stress in chronic periodontitis. in

Acta Pharmacologica Sinica (2013) 34: 247–254

- 28.Tu"ter, Serdar, Kurtisx, et al.. Effects of Scaling and Root Planing and Subantimicrobial Dose Doxycycline on Gingival Crevicular Fluid Levels of Matrix Metalloproteinase-8, -13 and Serum Levels of HsCRP in Patients With Chronic Periodontitis in J Periodontol 2010;81:1132-1139.
- 29.Sampath K. Rao, Swati Setty, Anirudh B. Acharya & Srinath L. Thakur. Efficacy of locally-delivered doxycycline microspheres in chronic localized periodontitis and on Porphyromonas gingivalis Journal of Investigative and Clinical Dentistry (2012), 3, 128–134.
- 30.Gu nur Emingil, Ali Gu"rkan, Gu Atilla, and Alpdog an Kantarci. Subantimicrobial-Dose Doxycycline and Cytokine-Chemokine Levels in Gingival Crevicular Fluid in J Periodontol 2011;82:452-461.
- 31.Anna Bogren, Ricardo P. Teles, Gay Torresyap, Anne D. Haffajee, Sigmund S. Socransky, and Jan L. Wennstro<sup>®</sup>m Locally Delivered Doxycycline During Supportive Periodontal Therapy: A 3-Year Study in J Periodontol 2008;79:827-835.
- 32.Gulnur Emingil, Gul Atilla, Timo Sorsa, and Taina Tervahartiala. The Effect of Adjunctive Subantimicrobial Dose Doxycycline Therapy on GCF EMMPRIN Levels in Chronic Periodontitis. in J Periodontol 2008;79:469-476
- 33.Ranjan Gupta, Nymphea Pandit, Shweta Agarwal and Ashish Verma . The Effect of Adjunctive Subantimicrobial Dose Doxycycline Therapy on GCF EMMPRIN Levels in Chronic Periodontitis in The Journal of Contemporary Dental Practice, 2008;9:7(1):1-15.

Conflict of interest: None					
Funding: None					
Cite this Article as: Slim L, Arora S, Gilani F.					
Efficacy Of Low Dose Doxycycline In The					
Treatment Of Periodontal Disease - A					
Systematic Review. Natl J Integr Res Med					
2021; Vol.12(4): 66-72					